Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer
Autor: | Nick Maisey |
---|---|
Rok vydání: | 2007 |
Předmět: |
Cancer Research
Necrosis medicine.drug_class medicine.medical_treatment Antineoplastic Agents urologic and male genital diseases Monoclonal antibody Clinical Trials Phase II as Topic Renal cell carcinoma medicine Humans Carcinoma Renal Cell Tumor Necrosis Factor-alpha Sunitinib business.industry Antibodies Monoclonal General Medicine medicine.disease Infliximab Kidney Neoplasms female genital diseases and pregnancy complications Thalidomide Cytokine Oncology Immunology Cancer research Tumor necrosis factor alpha medicine.symptom business medicine.drug |
Zdroj: | Cancer Investigation. 25:589-593 |
ISSN: | 1532-4192 0735-7907 |
Popis: | The kinase inhibitors sorafinib and sunitinib have demonstrated significant activity in renal cell carcinoma (RCC), and are now approved by the FDA for use in advanced disease. There still remains a need for novel therapies. Our group were the first to demonstrate activity of thalidomide in RCC, believed to be in part related to the modulation of tumor necrosis factor (TNF-a), a cytokine secreted by RCC with a number of tumor promoting properties. We subsequently conducted a phase II trial of the TNF-a monoclonal antibody infliximab in patients with previously treated advanced RCC. The drug was well tolerated. The response rate was 16% and stability was achieved in a further 16% of patients. Anti-TNF-a therapy may represent an important approach in the treatment of this disease. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |